市場調查報告書

尋常型天皰瘡(PV):市場洞察,流行病學,市場預測 (2027年)

Pemphigus Vulgaris (PV) - Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 629052
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
尋常型天皰瘡(PV):市場洞察,流行病學,市場預測 (2027年) Pemphigus Vulgaris (PV) - Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 2020年03月01日內容資訊: 英文
簡介

主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的尋常型天皰瘡(PV)的總患病數在2016年達6萬2,747人,同年的市場規模估計為7,403萬美元。

本報告提供尋常型天皰瘡(PV)市場相關調查,疾病概要,主要7個國家的市場趨勢,患病數及市場規模的變化與預測(過去2年、今後10年份),市場成長要素及障礙分析,開發中的治療藥的簡介,潛在成長性,目前未滿足需求等總括性彙整。

目錄

第1章 重要洞察

第2章 尋常型天皰瘡(PV)市場:概要

  • 市場佔有率(成果值)
  • 市場佔有率(預測值)

第3章 尋常型天皰瘡(PV)- 疾病背景和概要

  • 簡介
  • 臨床症狀
  • 病因
  • 發病機制
  • 病理生理學
  • 診斷
    • 國際專家小組的推薦事項

第4章 流行病學和患者人口

  • 主要的觀察
  • 病定義
  • 患者人口與預測參數
  • 主要7個國家尋常型天皰瘡(PV)的患病數
  • 主要7個國家尋常型天皰瘡(PV)的患病數:各重症度

第5章 尋常型天皰瘡(PV)的流行病學:各國

  • 美國
    • 尋常型天皰瘡(PV)的患病數
    • 尋常型天皰瘡(PV)的患病數:各重症度
    • 尋常型天皰瘡(PV)的診斷數
    • 尋常型天皰瘡(PV)的治療可能的病例數
  • 德國
    • 尋常型天皰瘡(PV)的患病數
    • 尋常型天皰瘡(PV)的患病數:各重症度
    • 尋常型天皰瘡(PV)的診斷數
    • 尋常型天皰瘡(PV)的治療可能的病例數
  • 法國
    • 尋常型天皰瘡(PV)的患病數
    • 尋常型天皰瘡(PV)的患病數:各重症度
    • 尋常型天皰瘡(PV)的診斷數
    • 尋常型天皰瘡(PV)的治療可能的病例數
  • 義大利
    • 尋常型天皰瘡(PV)的患病數
    • 尋常型天皰瘡(PV)的患病數:各重症度
    • 尋常型天皰瘡(PV)的診斷數
    • 尋常型天皰瘡(PV)的治療可能的病例數
  • 西班牙
    • 尋常型天皰瘡(PV)的患病數
    • 尋常型天皰瘡(PV)的患病數:各重症度
    • 尋常型天皰瘡(PV)的診斷數
    • 尋常型天皰瘡(PV)的治療可能的病例數
  • 英國
    • 尋常型天皰瘡(PV)的患病數
    • 尋常型天皰瘡(PV)的患病數:各重症度
    • 尋常型天皰瘡(PV)的診斷數
    • 尋常型天皰瘡(PV)的治療可能的病例數
  • 日本
    • 尋常型天皰瘡(PV)的患病數
    • 尋常型天皰瘡(PV)的患病數:各重症度
    • 尋常型天皰瘡(PV)的診斷數
    • 尋常型天皰瘡(PV)的治療可能的病例數

第6章 治療流程

  • 尋常型天皰瘡的治療方法:國際專家小組的推薦
  • 英國皮膚科學會的管理指南
  • 日本的尋常型天皰瘡的治療方法

第7章 未滿足需求

第8章 開發中的治療藥

  • 第二階段實驗階段的治療藥
  • ARGX-113:Argenx
    • 治療藥概要
    • 產品簡介
    • 其他開發活動
    • 臨床開發
    • 臨床試驗資訊
  • PRN1008:Principia Biopharma,Inc.
  • Rituximab (RG 105):Hoffmann-La Roche
  • VAY736:Novartis Pharmaceuticals

第9章 開發中止的治療藥

  • Ofatumumab:Novartis Pharmaceuticals

第10章 開發暫停中的治療藥

  • KC 706:Kemia

第11章 尋常型天皰瘡(PV):市場分析

  • 主要的觀察
  • 主要7個國家尋常型天皰瘡(PV)的市場規模
  • 主要7個國家尋常型天皰瘡(PV)的治療藥市場:各重症度
    • 輕度
    • 中等度
    • 重度

第12章 尋常型天皰瘡(PV)的市場規模:各國

  • 美國
    • 尋常型天皰瘡(PV)的市場規模
    • 尋常型天皰瘡(PV)的治療藥市場:各重症度
      • 輕度
      • 中等度
      • 重度
  • 歐盟5國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第13章 推動市場要素

第14章 市場障礙

第15章 附錄

第16章 調查手法

第17章 DelveInsight的服務內容

第18章 免責聲明

第19章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0927

DelveInsight's "Pemphigus Vulgaris (PV) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Pemphigus Vulgaris (PV) , historical and forecasted epidemiology as well as the Pemphigus Vulgaris (PV) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Pemphigus Vulgaris (PV) market report provides current treatment practices, emerging drugs, Pemphigus Vulgaris (PV) market share of the individual therapies, current and forecasted Pemphigus Vulgaris (PV) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Pemphigus Vulgaris (PV) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Pemphigus Vulgaris (PV) Disease Understanding and Treatment Algorithm

The DelveInsight Pemphigus Vulgaris (PV) market report gives a thorough understanding of the Pemphigus Vulgaris (PV) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Pemphigus Vulgaris (PV) .

Treatment

It covers the details of conventional and current medical therapies available in the Pemphigus Vulgaris (PV) market for the treatment of the condition. It also provides Pemphigus Vulgaris (PV) treatment algorithms and guidelines in the United States, Europe, and Japan.

Pemphigus Vulgaris (PV) Epidemiology

The Pemphigus Vulgaris (PV) epidemiology division provide insights about historical and current Pemphigus Vulgaris (PV) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Pemphigus Vulgaris (PV) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Pemphigus Vulgaris (PV) Epidemiology

The epidemiology segment also provides the Pemphigus Vulgaris (PV) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Pemphigus Vulgaris (PV) Drug Chapters

Drug chapter segment of the Pemphigus Vulgaris (PV) report encloses the detailed analysis of Pemphigus Vulgaris (PV) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Pemphigus Vulgaris (PV) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Pemphigus Vulgaris (PV) treatment.

Pemphigus Vulgaris (PV) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Pemphigus Vulgaris (PV) treatment.

Pemphigus Vulgaris (PV) Market Outlook

The Pemphigus Vulgaris (PV) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Pemphigus Vulgaris (PV) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Pemphigus Vulgaris (PV) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Pemphigus Vulgaris (PV) market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Pemphigus Vulgaris (PV) market in 7MM.

The United States Market Outlook

This section provides the total Pemphigus Vulgaris (PV) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Pemphigus Vulgaris (PV) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Pemphigus Vulgaris (PV) market size and market size by therapies in Japan is also mentioned.

Pemphigus Vulgaris (PV) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Pemphigus Vulgaris (PV) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Pemphigus Vulgaris (PV) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Pemphigus Vulgaris (PV) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Pemphigus Vulgaris (PV) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Pemphigus Vulgaris (PV) emerging therapies.

Reimbursement Scenario in Pemphigus Vulgaris (PV)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Pemphigus Vulgaris (PV) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Pemphigus Vulgaris (PV) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Pemphigus Vulgaris (PV) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Pemphigus Vulgaris (PV) , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Pemphigus Vulgaris (PV) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Pemphigus Vulgaris (PV) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Pemphigus Vulgaris (PV) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Pemphigus Vulgaris (PV) market

Report Highlights

  • In the coming years, Pemphigus Vulgaris (PV) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Pemphigus Vulgaris (PV) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Pemphigus Vulgaris (PV) . Launch of emerging therapies will significantly impact the Pemphigus Vulgaris (PV) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Pemphigus Vulgaris (PV)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Pemphigus Vulgaris (PV) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pemphigus Vulgaris (PV) Pipeline Analysis
  • Pemphigus Vulgaris (PV) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Pemphigus Vulgaris (PV) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Pemphigus Vulgaris (PV) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Pemphigus Vulgaris (PV) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Pemphigus Vulgaris (PV) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Pemphigus Vulgaris (PV) total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Pemphigus Vulgaris (PV) market size during the forecast period (2017-2030)?
  • At what CAGR, the Pemphigus Vulgaris (PV) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Pemphigus Vulgaris (PV) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Pemphigus Vulgaris (PV) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Pemphigus Vulgaris (PV) ?
  • What is the historical Pemphigus Vulgaris (PV) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Pemphigus Vulgaris (PV) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Pemphigus Vulgaris (PV) ?
  • Out of all 7MM countries, which country would have the highest prevalent population of Pemphigus Vulgaris (PV) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Pemphigus Vulgaris (PV) treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Pemphigus Vulgaris (PV) in the USA, Europe, and Japan?
  • What are the Pemphigus Vulgaris (PV) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Pemphigus Vulgaris (PV) ?
  • How many therapies are developed by each company for Pemphigus Vulgaris (PV) treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Pemphigus Vulgaris (PV) treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Pemphigus Vulgaris (PV) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Pemphigus Vulgaris (PV) and their status?
  • What are the key designations that have been granted for the emerging therapies for Pemphigus Vulgaris (PV) ?
  • What are the global historical and forecasted market of Pemphigus Vulgaris (PV) ?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Pemphigus Vulgaris (PV) market
  • To understand the future market competition in the Pemphigus Vulgaris (PV) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Pemphigus Vulgaris (PV) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Pemphigus Vulgaris (PV) market
  • To understand the future market competition in the Pemphigus Vulgaris (PV) market

Table of Contents

1. Key Insights

2. Executive Summary of Pemphigus Vulgaris (PV)

3. Competitive Intelligence Analysis for Pemphigus Vulgaris (PV)

4. Pemphigus Vulgaris (PV) : Market Overview at a Glance

  • 4.1. Pemphigus Vulgaris (PV) Total Market Share (%) Distribution in 2017
  • 4.2. Pemphigus Vulgaris (PV) Total Market Share (%) Distribution in 2030

5. Pemphigus Vulgaris (PV) : Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Pemphigus Vulgaris (PV) Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Pemphigus Vulgaris (PV) Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Pemphigus Vulgaris (PV) Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Pemphigus Vulgaris (PV) Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Pemphigus Vulgaris (PV) Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Pemphigus Vulgaris (PV) Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Pemphigus Vulgaris (PV) Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Pemphigus Vulgaris (PV) Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Pemphigus Vulgaris (PV) Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Pemphigus Vulgaris (PV) Treatment and Management
  • 8.2. Pemphigus Vulgaris (PV) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Pemphigus Vulgaris (PV) Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Pemphigus Vulgaris (PV) : Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Pemphigus Vulgaris (PV) Market Size in 7MM
  • 13.3. Pemphigus Vulgaris (PV) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Pemphigus Vulgaris (PV) Total Market Size in the United States
    • 15.1.2. Pemphigus Vulgaris (PV) Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Pemphigus Vulgaris (PV) Total Market Size in Germany
    • 15.3.2. Pemphigus Vulgaris (PV) Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Pemphigus Vulgaris (PV) Total Market Size in France
    • 15.4.2. Pemphigus Vulgaris (PV) Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Pemphigus Vulgaris (PV) Total Market Size in Italy
    • 15.5.2. Pemphigus Vulgaris (PV) Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Pemphigus Vulgaris (PV) Total Market Size in Spain
    • 15.6.2. Pemphigus Vulgaris (PV) Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Pemphigus Vulgaris (PV) Total Market Size in the United Kingdom
    • 15.7.2. Pemphigus Vulgaris (PV) Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Pemphigus Vulgaris (PV) Total Market Size in Japan
    • 15.8.3. Pemphigus Vulgaris (PV) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Pemphigus Vulgaris (PV)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1 : 7MM Pemphigus Vulgaris (PV) Epidemiology (2017-2030)
  • Table 2 : 7MM Pemphigus Vulgaris (PV) Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Pemphigus Vulgaris (PV) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Pemphigus Vulgaris (PV) Epidemiology in Germany (2017-2030)
  • Table 6 : Pemphigus Vulgaris (PV) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Pemphigus Vulgaris (PV) Epidemiology in France (2017-2030)
  • Table 8 : Pemphigus Vulgaris (PV) Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Pemphigus Vulgaris (PV) Epidemiology in Italy (2017-2030)
  • Table 10 : Pemphigus Vulgaris (PV) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Pemphigus Vulgaris (PV) Epidemiology in Spain (2017-2030)
  • Table 12 : Pemphigus Vulgaris (PV) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Pemphigus Vulgaris (PV) Epidemiology in the UK (2017-2030)
  • Table 14 : Pemphigus Vulgaris (PV) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Pemphigus Vulgaris (PV) Epidemiology in Japan (2017-2030)
  • Table 16 : Pemphigus Vulgaris (PV) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

The list of tables is not exhaustive; the final content may vary

List of Figures

  • Figure 1 : 7MM Pemphigus Vulgaris (PV) Epidemiology (2017-2030)
  • Figure 2 : 7MM Pemphigus Vulgaris (PV) Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Pemphigus Vulgaris (PV) Epidemiology in the United States (2017-2030)
  • Figure 4 : Pemphigus Vulgaris (PV) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Pemphigus Vulgaris (PV) Epidemiology in Germany (2017-2030)
  • Figure 6 : Pemphigus Vulgaris (PV) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Pemphigus Vulgaris (PV) Epidemiology in France (2017-2030)
  • Figure 8 : Pemphigus Vulgaris (PV) Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Pemphigus Vulgaris (PV) Epidemiology in Italy (2017-2030)
  • Figure 10 : Pemphigus Vulgaris (PV) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Pemphigus Vulgaris (PV) Epidemiology in Spain (2017-2030)
  • Figure 12 : Pemphigus Vulgaris (PV) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Pemphigus Vulgaris (PV) Epidemiology in the UK (2017-2030)
  • Figure 14 : Pemphigus Vulgaris (PV) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Pemphigus Vulgaris (PV) Epidemiology in Japan (2017-2030)
  • Figure 16 : Pemphigus Vulgaris (PV) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

The list of figures is not exhaustive; the final content may vary.